GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karyopharm Therapeutics Inc (NAS:KPTI) » Definitions » Cyclically Adjusted FCF per Share

KPTI (Karyopharm Therapeutics) Cyclically Adjusted FCF per Share : $-36.42 (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Karyopharm Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Karyopharm Therapeutics's adjusted free cash flow per share for the three months ended in Dec. 2024 was $-3.038. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-36.42 for the trailing ten years ended in Dec. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2025-05-11), Karyopharm Therapeutics's current stock price is $6.01. Karyopharm Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2024 was $-36.42. Karyopharm Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Karyopharm Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Karyopharm Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karyopharm Therapeutics Cyclically Adjusted FCF per Share Chart

Karyopharm Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -38.37 -37.32 -36.42

Karyopharm Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -37.32 -37.85 -37.64 -36.88 -36.42

Competitive Comparison of Karyopharm Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Karyopharm Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Karyopharm Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Karyopharm Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


;
;

Karyopharm Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Karyopharm Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-3.038/133.1571*133.1571
=-3.038

Current CPI (Dec. 2024) = 133.1571.

Karyopharm Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201503 -8.667 99.621 -11.585
201506 -12.057 100.684 -15.946
201509 -10.696 100.392 -14.187
201512 -8.762 99.792 -11.691
201603 -9.701 100.470 -12.857
201606 -8.719 101.688 -11.417
201609 -8.283 101.861 -10.828
201612 -7.252 101.863 -9.480
201703 -8.846 102.862 -11.451
201706 -7.110 103.349 -9.161
201709 -6.920 104.136 -8.849
201712 -1.707 104.011 -2.185
201803 -10.594 105.290 -13.398
201806 -10.170 106.317 -12.737
201809 -9.694 106.507 -12.120
201812 -12.170 105.998 -15.288
201903 -16.434 107.251 -20.404
201906 -11.867 108.070 -14.622
201909 -8.844 108.329 -10.871
201912 -9.277 108.420 -11.394
202003 -9.987 108.902 -12.211
202006 -8.253 108.767 -10.104
202009 -9.047 109.815 -10.970
202012 -6.256 109.897 -7.580
202103 -10.646 111.754 -12.685
202106 -11.121 114.631 -12.918
202109 -4.761 115.734 -5.478
202112 5.050 117.630 5.717
202203 -11.463 121.301 -12.583
202206 -6.618 125.017 -7.049
202209 -5.313 125.227 -5.649
202212 -4.472 125.222 -4.755
202303 -2.500 127.348 -2.614
202306 -3.375 128.729 -3.491
202309 -3.872 129.860 -3.970
202312 -2.429 129.419 -2.499
202403 -5.706 131.776 -5.766
202406 -3.739 132.554 -3.756
202409 -2.334 133.029 -2.336
202412 -3.038 133.157 -3.038

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Karyopharm Therapeutics  (NAS:KPTI) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Karyopharm Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Karyopharm Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Karyopharm Therapeutics Business Description

Traded in Other Exchanges
Address
85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Executives
Richard A. Paulson director, officer: President and CEO 85 WELLS AVENUE, NEWTON MA 02459
Stuart Poulton officer: EVP, Chief Development Officer 85 WELLS AVENUE, NEWTON MA 02459
Michael Mano officer: SVP, General Counsel&Secretary 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Sohanya Roshan Cheng officer: SVP Sales & Commercial Ops C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON MA 02459
Reshma Rangwala officer: EVP & Chief Medical Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Michael Mason officer: EVP, CFO, Treasurer 300 3RD STREET, CAMBRIDGE MA 02142
Deepika Pakianathan director 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Garen G Bohlin director C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451
Zhen Su director 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Stephen Mitchener officer: SVP, Chief Business Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Ran Frenkel officer: EVP, WW Development Operations C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, 2ND FLOOR, NEWTON MA 02459
Jatin Shah officer: EVP, Chief Medical Officer C/O KARYOPHARM THERAPEUTICS, INC., 85 WELLS AVENUE, NEWTON MA 02459
Sharon Shacham officer: C.S.O & Pres. of Res & Develop C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Michael Kauffman director, officer: President, C.E.O., C.M.O. C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Peter Honig director 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037